scholarly journals Renal glomerular lesions in children with juvenile rheumatoid arthritis (literature review)

KIDNEYS ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 42-47
Author(s):  
T.P. Borysova ◽  
S.V. Samsonenko ◽  
L.I. Vakulenko ◽  
O.O. Makoviichuk
Keyword(s):  
Rheumatoid Arthritis ◽  
Renal Failure ◽  
Literature Review ◽  
Immunosuppressive Therapy ◽  
Membranous Nephropathy ◽  
Minimal Change Disease ◽  
Minimal Change ◽  
Igm Nephropathy ◽  
Terminal Renal Failure ◽  
Glomerular Lesions

The literature review describes the different forms of glomerulonephritis (GN) in children with polyarticular and systemic forms of juvenile rheumatoid arthritis (JRA). In the available literature, there are 21 clinical cases of GN: ANCA-associated GN, mesangial proliferative GN, including IgA- and IgM-nephropathy, membranous nephropathy, focal-segmental glomerulosclerosis, minimal change disease, and extracapillary GN. The mechanism of glomerular lesions in JRA is explained by hyperproduction of pro-inflammatory cytokines and by nephrotoxic action of basal anti-inflammatory medications. The clinical manifestations and the effectiveness of treatment of each variant of GN in children with JRA were analyzed in detail. Most publications are devoted to ANCA-associated GN, which developed in patients with a torpid course and a high activity of polyarticular and systemic forms of JRA. The peculiarity of ANCA-associated GN was the presence of hypercreatininemia and in almost half of cases the development of terminal renal failure, despite conducted immunosuppressive therapy. Single cases of other variants of GN were described more than 10 years ago. Proteinuria and the rare nephrotic syndrome were clinically observed, which was the reason for intravital renal morphological examination. Immunosuppressive therapy was effective in mesangial proliferative GN and minimal change disease. All cases of focal-segmental glomerulosclerosis, extracapillary GN were accompanied by the formation of terminal renal failure. Favorable prognosis appeared in children with drug-induced membranous nephropathy after their withdrawal. There are publications on a positive therapeutic effect of genetically engineered biological drugs in ANCA-associated GN, IgM-nephropathy, and a hormone-resistant variant of MCD in children with JRA.

scholarly journals Atypical presentation of rheumatoid arthritis: a case of massive bilateral pleural effusions in a patient with Caplan syndrome

2019 ◽  
Vol 12 (10) ◽  
pp. e231899
Author(s):  
Yinglun Wu ◽  
Philip C Dittmar
Keyword(s):  
Rheumatoid Arthritis ◽  
Atrial Fibrillation ◽  
Pleural Effusion ◽  
Connective Tissue ◽  
Minimal Change Disease ◽  
Connective Tissue Disorder ◽  
Minimal Change ◽  
Atypical Presentation ◽  
Pleural Effusions ◽  
Recent Treatment

Rheumatoid arthritis (RA) is a common connective tissue disorder affecting the synovial joints. In patients with RA, involvement of the lungs occurs in 30%–40% of cases while pleural effusions occur in only 3%–5%. However, the majority of RA-associated pleural effusions are small, unilateral and asymptomatic. We present a case of massive bilateral pleural effusions in a patient with established rheumatoid pneumoconiosis (Caplan syndrome). Interestingly, the pleural effusion occurred following recent treatment for minimal change disease and atrial fibrillation.

scholarly journals Development and Validation of a Discrimination Model Between Primary PLA2R-Negative Membranous Nephropathy and Minimal Change Disease Confirmed by Renal Biopsy

2020 ◽  
Author(s):  
Feng Wu ◽  
Yiding Zhang ◽  
Wen Cui ◽  
Yijun Dong ◽  
Yingyang Geng ◽  
...  
Keyword(s):  
Renal Biopsy ◽  
Membranous Nephropathy ◽  
Minimal Change Disease ◽  
Multivariate Logistic Regression Analysis ◽  
Test Group ◽  
Minimal Change ◽  
Clinical Feature ◽  
Specific Marker ◽  
Discrimination Model ◽  
Phospholipase A2 Receptor

Abstract BackgroundMembranous nephropathy (MN) and minimal change disease (MCD) are two common causes leading to nephrotic syndrome (NS). They have similar clinical feature but different treatment strategy and prognosis. M-type phospholipase A2 receptor (PLA2R) is considered as a specific marker of membranous nephropathy. However, its sensitivity is only about 70%. Therefore, there is a lack of effective and noninvasive tools to distinguish PLA2R-negative MN and MCD patients without renal biopsy. We aim to develop a discrimination model using noninvasive parameters for distinguishing the two diseases and support immediate treatment before result of renal biopsy.MethodsA total 949 patients who were pathologically diagnosed as idiopathic MN or primary MCD in the First Affiliated Hospital of Zhengzhou University from January 2017 to August 2019 were enrolled in this study, including 805 idiopathic MN (605 PLAR2-positive MN and 200 PLA2R-negative MN) and 144 primary MCD. Based on the basic information and laboratory examination of 200 PLA2R-negative MN and 144 MCD, we used univariate and multivariate logistic regression analysis to select the relevant variables and develop the discrimination model. ROC curves and calibration curves were used to evaluate the diagnostic ability and calibration ability of the model. The decision curve was used to show the net benefit. We also tested the effectiveness of our model in all 949 patients.ResultsA novel model that included age, albumin, urea, high density lipoprotein, urea and red blood cell count was established for PLA2R-negative MN and MCD. The discrimination model has good differential capability (an AUC of 0.889 in training group and an AUC of 0.920 in test group) and calibration capability. When testing in all 949 patients, our model also showed good discrimination ability for all idiopathic MN and MCD.ConclusionWe constructed a discrimination model with high diagnostic effectiveness for PLA2R-negative MN and MCD. The model could also be used for all idiopathic MN and MCD patients.

scholarly journals Development and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and minimal change disease confirmed by renal biopsy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Feng Wu ◽  
Yiding Zhang ◽  
Wen Cui ◽  
Yijun Dong ◽  
Yingyang Geng ◽  
...  
Keyword(s):  
Renal Biopsy ◽  
Membranous Nephropathy ◽  
Minimal Change Disease ◽  
Treatment Strategies ◽  
Test Group ◽  
Minimal Change ◽  
Specific Marker ◽  
Discrimination Ability ◽  
Discrimination Model ◽  
Phospholipase A2 Receptor

AbstractMembranous nephropathy (MN) and minimal change disease (MCD) are two common causes leading to nephrotic syndrome (NS). They have similar clinical features but different treatment strategies and prognoses. M-type phospholipase A2 receptor (PLA2R) is considered as a specific marker of membranous nephropathy. However, its sensitivity is only about 70%. Therefore, there is a lack of effective and noninvasive tools to distinguish PLA2R-negative MN and MCD patients without renal biopsy. A total 949 patients who were pathologically diagnosed as idiopathic MN or MCD were enrolled in this study, including 805 idiopathic MN and 144 MCD. Based on the basic information and laboratory examination of 200 PLA2R-negative MN and 144 MCD, we used a univariate and multivariate logistic regression to select the relevant variables and develop a discrimination model. A novel model including age, albumin, urea, high density lipoprotein, C3 levels and red blood cell count was established for PLA2R-negative MN and MCD. The discrimination model has great differential capability (with an AUC of 0.904 in training group and an AUC of 0.886 in test group) and calibration capability. When testing in all 949 patients, our model also showed good discrimination ability for all idiopathic MN and MCD.

Response Predictors to Calcineurin Inhibitors in Patients with Primary Membranous Nephropathy

2018 ◽  
Vol 47 (4) ◽  
pp. 266-274 ◽  
Author(s):  
Xiaofang Yu ◽  
Jieru Cai ◽  
Xiaoyan Jiao ◽  
Shu Zhang ◽  
Hong Liu ◽  
...  
Keyword(s):  
Roc Curve ◽  
Membranous Nephropathy ◽  
Minimal Change Disease ◽  
Operating Characteristic ◽  
Calcineurin Inhibitors ◽  
Minimal Change ◽  
Ms Analysis ◽  
Response Predictors ◽  
Phospholipase A2 Receptor ◽  
Serum Amyloid A1

Background: Currently, there is an urgent need to find ways of identifying primary membranous nephropathy (PMN) patients who are likely to benefit from calcineurin inhibitors (CNI) or who are resistant to them. In this study, we employed nano-HPLC-MS/MS analysis to identify serum biomarkers that predict the clinical response to CNI therapy in PMN patients. Methods: The endpoint was complete remission (CR) after CNI treatment. PMN patients were grouped into no-remission (NR) or CR groups to screen predictive candidates using the nano-HPLC-MS/MS analysis. Results: Compared with NR patients, 3 upregulated proteins and 5 downregulated proteins were found to present a twofold change in CR patients’ serum. Serum amyloid A1 protein (SAA1) was further validated by ELISA; it was decreased in patients in the NR group compared with patients in the CR group, but SAA1 in patients in these groups was lower than in healthy controls and minimal change disease patients. The area under the receiver operating characteristic (ROC) curve of SAA1 was used to distinguish PMN NR patients from those in remission and was 0.901, with a sensitivity of 78.3% and specificity of 86.8%, similar to that of the phospholipase A2 receptor (PLA2R) antibody. Combining SAA1 with the PLA2R antibody, the area under the ROC curve was 0.956, which was higher than that of SAA1 or the PLA2R antibody alone. Conclusions: Serum SAA1 may be a candidate PMN biomarker that can be used to discriminate CNI NR cases from remission patients. The combination of SAA1 and the PLA2R antibody increases the accuracy of diagnosis.

scholarly journals KIDNEY DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS

2019 ◽  
Vol 19 (2) ◽  
pp. 246-250
Author(s):  
L.A. Tkachenko ◽  
U.A. Kostrikova ◽  
T.I. Yarmola ◽  
G.L. Pustovoit ◽  
V.V. Talash
Keyword(s):  
Rheumatoid Arthritis ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Renal Damage ◽  
Relevant Literature ◽  
Kidney Damage ◽  
Renal Amyloidosis ◽  
Predominant Role ◽  
Terminal Renal Failure ◽  
Uremic Syndrome

The purpose of this work is to perform a general analysis of relevant literature on the issue of kidney damage in patients with rheumatoid arthritis. Kidney damage in patients with rheumatic diseases is potentially dangerous, as it can lead to the development of terminal renal failure that may require replacement renal therapy. Amyloidosis often leads to kidney failure in patients with rheumatoid arthritis. Renal amyloidosis more often develops in patients with acute course of rheumatoid arthritis and under maximal immunological disorders. In patients with renal amyloidosis against the background of rheumatoid arthritis, manifestations of joint affection decrease, while the renal-uremic syndrome takes a predominant role. Signs of nephrotic syndrome and chronic renal failure develop gradually. Kidney damage can be caused by medications for rheumatoid arthritis. The choice of the optimal scheme of individual-centred therapy is vitally important for patients, since every aggravation of both rheumatic disease and secondary renal damage leads to the progression of chronic renal failure.

scholarly journals MINIMAL CHANGE DISEASE IN THERAPEUTIC PRACTICE

2021 ◽  
Vol 14 (5) ◽  
Author(s):  
OLGA N. SIGITOVA ◽  
◽  
RUSTEM I. SHAYMURATOV ◽  
ROZALIA R. SHARIPOVA ◽  
LILYA KH. SAFARGALIYEVA ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Immunosuppressive Therapy ◽  
Clinical Case ◽  
Minimal Change Disease ◽  
Current Data ◽  
Minimal Change ◽  
Steroid Resistance ◽  
Original Research ◽  
Relapsed Disease ◽  
Progressive Course

The disease of minimal changes occurs in 10–15% of adult patients with idiopathic nephrotic syndrome, it often has a relapsing course. Glucocorticoids are effective in achieving remission, but in some patients steroid resistance and progressive course of the disease are observed. Recent studies have investigated the mechanismsof minimal change disease development for the purpose of estimating the prognosis of the disease and the efficacy of immunosuppressive therapy. Aim. The aim of the present study was to review current data on the diagnosis, pathogenetic therapy of minimal change disease, and to demonstrate the clinical case of a relapsed disease in steroid resistant patient. Material and methods. A review of original research in the foreign and domestic literature on the subject over the past 5 years was conducted. Results and discussion. Minimal change disease is clinically manifested by rapid, almost sudden development of nephrotic syndrome (proteinuria, hypoalbuminemia, marked hypercholesterolemia, and massive generalized edema). Arterial hypertension and microhematuria occur occasionally. Glucocorticoids are being prescribed to achieve early remission even before morphological verification of the diagnosis. The course of the disease is mostly benign. The majority of patients with steroid sensitivity have long-term preserved renal function, while steroid resistance is associated with a progressive course leading to terminal renal failure. The presented clinical case is interesting because the unfolded picture of the disease of minimal changes including severe nephrotic syndrome and steroid-resistance, appeared in the patient a year after the disease debut. After receiving combined immunosuppressive therapy for 16 weeks incomplete remission was achieved. Conclusion. Unfortunately, at present, there are no available reliable methods to predict the development of steroid resistance and there are no effective therapies guaranteeing the achievement of remission in such cases.

Sign in / Sign up

Export Citation Format

Share Document